Antibiotic and antiviral prescribing patterns among hospitalised patients with COVID-19 pneumonia in Mongolia: a real-world descriptive retrospective study.

IF 2.6 Q1 HEALTH POLICY & SERVICES
Journal of Pharmaceutical Policy and Practice Pub Date : 2026-09-18 eCollection Date: 2026-01-01 DOI:10.1080/20523211.2026.2731647
Narangarav Nyamdag, Nina Muratkhan, Munkhbat Sukhee, Erdenetuya Myagmarsuren
{"title":"Antibiotic and antiviral prescribing patterns among hospitalised patients with COVID-19 pneumonia in Mongolia: a real-world descriptive retrospective study.","authors":"Narangarav Nyamdag, Nina Muratkhan, Munkhbat Sukhee, Erdenetuya Myagmarsuren","doi":"10.1080/20523211.2026.2731647","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>During the COVID-19 pandemic, Mongolia, like many low- and middle-income countries, faced major healthcare delivery challenges due to limited system readiness, resource constraints, geopolitical vulnerabilities, and prolonged border closures. These factors caused shortages of laboratory reagents and globally recommended therapeutics, including remdesivir and tocilizumab, prompting clinicians to use alternative antivirals and empirical broad-spectrum antibiotics.</p><p><strong>Objective: </strong>To evaluate and compare real-world prescribing patterns of antibiotics and antivirals among hospitalised patients with COVID-19 pneumonia at Mongolia's two largest tertiary referral facilities: Mongolia-Japan Hospital (MJH) and the National Center for Communicable Diseases (NCCD).</p><p><strong>Methods: </strong>This retrospective cross-sectional study analysed anonymised medical charts and electronic health records of 1012 adults with PCR-confirmed COVID-19 pneumonia hospitalised between 18 April and 31 December 2021. Demographics, comorbidities, laboratory markers, and pharmacological treatments were systematically extracted and compared between the two institutions.</p><p><strong>Results: </strong>Antibiotics were prescribed to 87.6% (887/1012) of patients. Cephalosporins were the most frequently prescribed class (89.3%, 904/1012), followed by macrolides (36.5%, 369/1012) and fluoroquinolones (33.5%, 339/1012). Multi-drug empiricism was common, with beta-lactam, macrolide, and quinolone combinations accounting for 70.8% (68/96) of triple-antibiotic regimens. Antivirals were administered to over 90% of patients, predominantly umifenovir (52.2%) and favipiravir, supported by domestic stockpiles and Eurasian trade networks. Remdesivir was rarely used, while tocilizumab was administered to only 2 patients (0.2%). Hypertension and diabetes were significantly more frequent in the MJH cohort, reflecting differences in catchment populations and screening practices.</p><p><strong>Conclusion: </strong>The high rate of empirical broad-spectrum antibiotic use and reliance on alternative antivirals reflect pragmatic clinical adaptations to diagnostic reagent shortages and therapeutic supply inequities. These findings highlight the need for national antimicrobial stewardship programmes, strengthened microbiological diagnostic capacity, and digitised clinical registries to improve healthcare system resilience in resource-constrained settings.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"19 1","pages":"2731647"},"PeriodicalIF":2.6000,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591967/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2026.2731647","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: During the COVID-19 pandemic, Mongolia, like many low- and middle-income countries, faced major healthcare delivery challenges due to limited system readiness, resource constraints, geopolitical vulnerabilities, and prolonged border closures. These factors caused shortages of laboratory reagents and globally recommended therapeutics, including remdesivir and tocilizumab, prompting clinicians to use alternative antivirals and empirical broad-spectrum antibiotics.

Objective: To evaluate and compare real-world prescribing patterns of antibiotics and antivirals among hospitalised patients with COVID-19 pneumonia at Mongolia's two largest tertiary referral facilities: Mongolia-Japan Hospital (MJH) and the National Center for Communicable Diseases (NCCD).

Methods: This retrospective cross-sectional study analysed anonymised medical charts and electronic health records of 1012 adults with PCR-confirmed COVID-19 pneumonia hospitalised between 18 April and 31 December 2021. Demographics, comorbidities, laboratory markers, and pharmacological treatments were systematically extracted and compared between the two institutions.

Results: Antibiotics were prescribed to 87.6% (887/1012) of patients. Cephalosporins were the most frequently prescribed class (89.3%, 904/1012), followed by macrolides (36.5%, 369/1012) and fluoroquinolones (33.5%, 339/1012). Multi-drug empiricism was common, with beta-lactam, macrolide, and quinolone combinations accounting for 70.8% (68/96) of triple-antibiotic regimens. Antivirals were administered to over 90% of patients, predominantly umifenovir (52.2%) and favipiravir, supported by domestic stockpiles and Eurasian trade networks. Remdesivir was rarely used, while tocilizumab was administered to only 2 patients (0.2%). Hypertension and diabetes were significantly more frequent in the MJH cohort, reflecting differences in catchment populations and screening practices.

Conclusion: The high rate of empirical broad-spectrum antibiotic use and reliance on alternative antivirals reflect pragmatic clinical adaptations to diagnostic reagent shortages and therapeutic supply inequities. These findings highlight the need for national antimicrobial stewardship programmes, strengthened microbiological diagnostic capacity, and digitised clinical registries to improve healthcare system resilience in resource-constrained settings.

蒙古COVID-19肺炎住院患者的抗生素和抗病毒药物处方模式:一项真实世界的描述性回顾性研究
背景:在2019冠状病毒病大流行期间,蒙古与许多低收入和中等收入国家一样,由于系统准备不足、资源限制、地缘政治脆弱性和长期边境关闭,面临着重大的医疗保健服务挑战。这些因素导致实验室试剂和全球推荐的治疗药物(包括remdesivir和tocilizumab)短缺,促使临床医生使用替代抗病毒药物和经验性广谱抗生素。目的:评估和比较蒙古两家最大的三级转诊机构:蒙日医院(MJH)和国家传染病中心(NCCD)住院的COVID-19肺炎患者的抗生素和抗病毒药物的实际处方模式。方法:本回顾性横断面研究分析了2021年4月18日至12月31日期间1012名经pcr确诊的成人COVID-19肺炎住院患者的匿名病历和电子健康记录。系统地提取和比较两所医院的人口统计、合并症、实验室标志物和药物治疗。结果:87.6%(887/1012)的患者使用抗生素。头孢菌素类是最常见的处方类(89.3%,904/1012),其次是大环内酯类(36.5%,369/1012)和氟喹诺酮类(33.5%,339/1012)。多药经验主义比较普遍,β -内酰胺类、大环内酯类和喹诺酮类联合使用占三抗生素方案的70.8%(68/96)。在国内库存和欧亚贸易网络的支持下,90%以上的患者使用了抗病毒药物,主要是乌米诺韦(52.2%)和法匹拉韦。很少使用Remdesivir,而tocilizumab仅用于2例患者(0.2%)。高血压和糖尿病在MJH队列中明显更常见,反映了集水区人群和筛查方法的差异。结论:广谱抗生素的高使用率和对替代抗病毒药物的依赖反映了临床对诊断试剂短缺和治疗供应不公平的实际适应。这些发现强调需要制定国家抗菌素管理规划、加强微生物诊断能力和数字化临床登记,以提高资源受限环境下卫生保健系统的复原力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmaceutical Policy and Practice
Journal of Pharmaceutical Policy and Practice Health Professions-Pharmacy
CiteScore
4.70
自引率
9.50%
发文量
81
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书